Impact of Primary Tumor Resection on Bone Metastatic BC

Nayu Kitsuya and the team aimed to investigate whether primary tumor resection in patients with bone metastatic breast cancer (BC) impacts survival, utilizing the Surveillance, Epidemiology, and End Results database while considering subtype classification.

Researchers performed an inclusive analysis, encompassing all female patients diagnosed with bone metastatic BC at initial presentation from 2010 to 2016, with documented hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) statuses. Exclusion criteria comprised cases with unknown cause of death or unknown HR/HER2 status. Survival analysis entailed Cox proportional hazards modeling to calculate hazard ratios (HZR).

About 13,450 patients were included, with 2,073 HR+/HER2+, 8,597 HR+/HER2-, 797 HR-/HER2+, and 1,182 triple-negative cases. Five-year overall survival rates were 34.5% (HR+/HER2+), 26.0% (HR+/HER2-), 29.2% (HR-/HER2+), and 8.0% (triple-negative). Triple-negative patients exhibited the worst overall survival (HR+/HER2+: HZR=2.1, 95% CI=1.9-2.3; HR+/HER2-: HZR=2.4, 95% CI=2.2-2.6; HR-/HER2+: HZR=1.5, 95% CI=1.3-1.6). After excluding early deaths, primary tumor resection prolonged survival in all subtypes except HR-/HER2+.

The study concluded that patients with triple-negative bone metastatic BC exhibited unfavorable survival. Primary tumor resection prolonged survival in each subtype except for HR-/HER2+.

Source: https://pubmed.ncbi.nlm.nih.gov/38537990/

Kitsuya N, Matsuoka M, Onodera T, et al. (2024). “Surgical Resection of Primary Tumor for Bone Metastatic Breast Cancer Patients at Initial Presentation.” Anticancer Res. 2024 Apr;44(4):1591-1601. doi: 10.21873/anticanres.16957. PMID: 38537990.